Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multiple myeloma

- PMLiVE

After discount row, NICE finally says yes to first line Revlimid

England catches up with rest of Europe

- PMLiVE

Pfizer’s alliance with Sosei Heptares bears first fruit

Partners focusing on GPCR-targeting drugs

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Speedy approval for Pfizer’s Onpattro rival

Approved in two different formulations

- PMLiVE

Solid Q1 results lift Pfizer as it waits for pipeline boost

Shares rose almost 2% in the wake of the presentation

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

GSK’s myeloma drug hits target, prompting rapid filing pledge

Antibody drug conjugate could challenge CAR-Ts

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links